As per the report, the size of the global dendritic cell cancer vaccines market is forecasted to grow at a robust CAGR from 2021 to 2026.
Human tumors express several protein antigens that can be recognized by T cells; thus, it provides potential targets for cancer therapy. Dendritic cells are rare leukocytes that are uniquely potent in their ability to present antigen to the T cells; according to WHO, around 9.6 million people died in 2018. Also, about 300000 cases were detected in children of the age 0 – 19 years. The isolated dendritic cells are loaded with tumor antigen ex vivo. They are administrated as a cellular vaccine and have been found to induce protective and therapeutic anti-tumor immunity during the experiment. Cancer vaccine is a market that researchers and patients have highly valued since it leads to a high survival rate and fewer possibilities of cancer recurrence; consequently, the inclusion of dendritic cells into cancer vaccine is predicted to enhance further vaccines' functioning mechanism against different sorts of cancers.
Growing incidence of cancer across the world and raising funds for the development of new vaccine-related diseases from the public and private organizations are majorly promoting the global dendritic cell cancer vaccines market.
The allogeneic dendritic cells are used to create a vaccine for COVID-19. On-going research on the development of vaccines to cure tumor cells is escalating the demand of the market. Increasing disposable income in developed and developing countries is leveling up the growth rate of the market.
The vast understanding of vaccines in creating an immune response necessary against cancer cells is an essential feature contributing to the market's progressive adoption in the present cancer treatments sector. The development of a worldwide dendritic cancer cell vaccination for patients with various malignancies is expected to provide considerable potential for millions of patients. The therapeutics market's overall success has a significant impact on research, technology, and pharmaceuticals. The potential of dendritic cells to target various cancer antigens, the growth in the elderly population, and technological improvements are driving this market forward. Oncologists might utilize computer technology to build and run replications on hypothetical immunizations to examine how they influence cellular forms before turning to lab testing and wasting money on pricey resources. Due to the existing unmet demand for safe and efficient cancer therapies with fewer side effects, as well as the inherent benefits of dendritic cells, oncologists believe this market would bring significant economic potential.
Additionally, current and new technological platforms to develop novel cancer vaccine variations are propelling the global dendritic cell cancer vaccine market growth. Many studies have shown dendritic cells have the potential ability in combinational therapies to restrict cancer growth. The growth of the dendritic cell cancer vaccine market is expected to be fuelled by increased investments in research & development and excellent clinical trial findings. Owing to a lucrative development in the pipeline, the global dendritic cells vaccines market has managed to catch the attention of numerous important investors and stakeholders. Furthermore, the Partnerships in the regional market that have recently taken places, such as clinical trial collaborations and research collaborations, have aided the global dendritic cell cancer vaccines market expansion.
The growth of the global dendritic cell cancer vaccine market is progressively diminishing due to a lack of understanding of using vaccinations in various forms. The government's strict restrictions and restrictions are also limiting the market for dendritic cell vaccines. The market's development pace is also being slowed by a scarcity of experienced personnel at research institutes.
Impact of COVID-19 on the global dendritic cell cancer vaccines market:
The cancer vaccine market substantially affected the growth due to the abrupt advent of the worldwide pandemic COVID-19. Around 210 nations have been affected by COVID-19. COVID-19 has had a limited impact on cancer vaccine production and distribution enterprises, owing to shutdowns in several COVID-19-affected countries and a rise in the number of healthcare personnel becoming ill due to the pandemic, resulting in a shortage. As the number of COVID-19 cases increased globally, healthcare systems turned their priority to containing the illness, delaying the prevention, diagnosis, and treatment of other chronic diseases such as cancer. As a result, the cancer vaccine market is now predicted to have a negative impact. However, due to the removal of limitations and the resumption of R&D activities and clinical trials for cancer vaccines, the market is likely to gain traction in the future years.
Market Size Available
2021 to 2026
2021 to 2026
By Product Type, End-User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This market research report on the global dendritic cell cancer vaccines market has been segmented based on the product type, end-user, and region.
Dendritic Cell Cancer Vaccines Market - By Product Type:
Based on product type, the Provenge segment accounted for the largest market share of the Dendritic cell cancer vaccine market in 2020. The drug sipuleucel-T has been authorized for use in males with metastatic prostate cancer. As it grows in popularity During the projection period, Sipuleucel-T is expected to increase its market share. Melanoma, prostate cancer, and other cancers are treated with it. The FDA gave it its approval nearly seven years ago. As it is, the market leader continues to its growth during the forecast period.
Dendritic Cell Cancer Vaccines Market - By End User:
Dendritic Cell Cancer Vaccines Market - By Region:
Regionally, North American captured the highest share in the global market. The United States leads the market in North America. Europe is not far behind and is expected to close in on the North American market in the forecast mentioned above period. The UK is the market leader in this region.
The Asia Pacific will continue its high growth spurt until 2024. The booming economies of India and China are spearheading this spectacular growth. Latin America and MEA continue to lag and will remain the least attractive markets all through the forecast period.
KEY MARKET PARTICIPANTS:
Some of the promising companies operating in the global dendritic cell cancer vaccines market profiled in the report are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation, Elios Therapeutics, ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, and Merck & Co.
RECENT MARKET DEVELOPMENTS:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.3 Sipuleucel-T (Provenge)
5.1.5 Y-o-Y Growth Analysis, By Product Type
5.1.6 Market Attractiveness Analysis, By Product Type
5.1.7 Market Share Analysis, By Product Type
5.2 End User
5.2.4 Y-o-Y Growth Analysis, By End User
5.2.5 Market Attractiveness Analysis, By End User
5.2.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product Type
220.127.116.11 By End User
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product Type
126.96.36.199 By End User
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product Type
220.127.116.11 By End User
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 3M Company
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.3 Argos Therapeutics
8.4 Batavia Bioservices
8.5 Bellicum Pharmaceuticals
8.7 DanDrit Biotech
8.9 Sanpower Corporation (Dendreon Corporation)
8.10 Elios Therapeutics
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures